Inspecting the screen at the population level to identify the average benefit of each third agent over the DNR-AraC backbone alone, akin to parallel clinical trials, confirmed the benefit of adding venetoclax or selinexor to DNR-AraC, both regimens being currently tested in clinical trials [34, 35], but also revealed a significant activity of the addition of the JAK inhibitor ruxolitinib (q < 10−5, Fig. 6a), which has so far been explored in patients with AML secondary to myeloproliferative neoplasms [36], but never in the setting of NPM1 mutations. Here, NPM1 is linked to myeloproliferative neoplasm.